MINAP National Audit of Myocardial Infarction

1
MINAPNational Audit of Myocardial Infarction

• Compiled by J S Birkhead
• Clinical Director
• National Audit of Myocardial Infarction

Please see PowerPoint notes pages for general and
specific comments and Advice on the use of these
images
2
Final Diagnosis and Reperfusion Treatment

• Group a

2
3
Final Diagnosis
3
4
Final compacted diagnosis by year
4
5
Final Diagnosis
5
6
ECG appearances on which treatment was based for
2004
6
7
Use of lytic agents 2004
7
8
Use of lytic agents 2004 n23335
8
9
Reperfusion treatment by year
9
10
Where thrombolytic treatment is given
10
11
Type of reperfusion treatment
11
12
Type of reperfusion treatment
12
13
Percentage of patients having lytic treatment
within 30 minutes of arrival in hospital mean
and 95 CI
13
14
Delays from onset to lytic treatment
14
15
Delays to lysis and PPCI 2004
15
16
Onset to reperfusion
16
17
Onset to thrombolytic treatment admission
diagnosis of STE MI
17
18
Some factors having an impact on mortality after
infarction

• Group b

18
19
Mortality after Acute Coronary Syndromes
Cumulative 13.6 Blue 10.6 Green 11.6 Red
19
20
35 day mortality for patients treated with
thrombolytic drugs within 6 h. (admission ECG
STE MI)
20
21
Characteristics of patients havingthrombolytic
treatment
21
22
Time to call for help (median IQR) throughout
24 hours
22
23
Median time to call for help and onset to
treatment in each 2 hr interval patients with a
final diagnosis of STE MI
23
24
Delay to thrombolytic treatment vs age (in
hospital mortality)
24
25
Care for patients with hyperglycaemia

• Group c

25
26
Frequency of diabetes in ACS
26
27
90 day mortality non diabetics and diet control
diabetics not having treatment during admission
27
28
Mortality _at_90 days diabetics (n 4500) and non
diabetics (n 14500)
28
29
90 day mortality by admission sugar
quartilepatients not known to be diabetic, n
10147
29
30
Patients not known to be diabetic having
diabetic treatment
30
31
Hospital treatment upper quartile (admission
glucose gt 8.7 mmol)
31
32
Secondary prevention drugs

• Group d

32
33
Use of secondary prevention medication for
marker positive ACS 2000-2005
33
34
Use of secondary prevention medication for
elderly (gt 75 years) patients with marker
positive ACS
34
35
Odds ratio of death at 30 days for hospital
survivors of ACS
35
36
Co-morbidity for patients presenting with an
acute coronary syndrome

• Group e

36
37
Comorbidity with ACS2004 data
37
38
Comorbidity with ACS2004 data
CCF, treated heart failure COPD, chronic
obstructive airways disease or asthma CRF,
chronic renal failure CVSd, Cerebrovascular
disease PVD, peripheral vascular disease
38